Home › Compound Library › Triamcinolone

Triamcinolone

Corticosteroidprescriptionoral · inferred

Intermediate-acting synthetic glucocorticoid with oral bioavailability ~23% due to extensive presystemic metabolism. Low systemic bioavailability makes it suitable for topical/inhalational use with minimal systemic effects. Plasma half-life ~2-3 hours but biologic duration longer. CYP3A4 substrate metabolized hepatically; little parent compound detected in plasma 24 hours post-dose. Used intra-articularly, nasally, or systemically for inflammation.

Projected serum levels — 8 mg, once daily

Triamcinolone
Triamcinolone modeled serum levels, 8 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 0.50 1 1.5 2 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 8 mg once daily (oral).

Modeled steady state after ~1 days: peak ≈ 1.3 mg, trough ≈ 0.001 mg body load. Population-based estimate over 15 days for a 8 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Corticosteroid
Route modeled
Oral
Model confidence
inferred
Half-life
2 h
Common dose
8 mg
Suggested maximum
60 mg/day
Reference dose range
4–60 mg (single dose)
Suggested cadence
once daily
Validated against
8 mg oral — Cmax 0.011 mg/L at 1 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Triamcinolone CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Triamcinolone AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Triamcinolone CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Triamcinolone AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Triamcinolone CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Triamcinolone AUC by ~5.00x

  • contraindicated
    Diltiazem + Triamcinolone CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Triamcinolone AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Triamcinolone CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Triamcinolone AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Triamcinolone CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Triamcinolone AUC by ~10.00x

Serum checks 72 modeled interaction pairings for triamcinolone across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration Derendorf H et al. · Journal of Clinical Pharmacology, 1995 DOI

    PK study in healthy subjects showing oral bioavailability 23%, Cmax 10.5 ng/mL at 1 hour, IV half-life 2.0 hours, volume of distribution 103 L, inhalational bioavailability 22%.

  2. A mass balance study to evaluate the biotransformation and excretion of [14C]-triamcinolone acetonide following oral administration Frey BM et al. · Clinical Pharmacology & Therapeutics, 2000 DOI

    Radiolabeled mass balance study demonstrating systemic absorption with extensive presystemic metabolism via CYP3A4; little parent compound in plasma 24 hours, supporting low systemic exposure rationale.

  3. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration Rohatagi S et al. · Journal of Clinical Pharmacology, 1995 DOI

    Comprehensive PK/PD evaluation showing dose-dependent cortisol suppression paralleling plasma triamcinolone; inhaled route preferred for respiratory use due to high local lung deposition with minimal systemic absorption.

3 published studies referenced in the app, each with a plain-language summary.